Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
作者： V. Fonseca , A. Schweizer , D. Albrecht , M. A. Baron , I. Chang
DOI: 10.1007/S00125-007-0633-0
关键词: Endocrinology 、 Internal medicine 、 Type 2 diabetes 、 Glucagon secretion 、 Insulin 、 Pancreatic hormone 、 Vildagliptin 、 Medicine 、 Dipeptidyl peptidase-4 、 Hypoglycemia 、 Tolerability
摘要: … and tolerability of vildagliptin added to insulin … Vildagliptin decreases HbA 1c in patients whose type 2 diabetes is poorly controlled with high doses of insulin. Addition of vildagliptin to …
springer.com
paperity.org参考文章(18)
Jawad A. Al-Lawati, Ali J. Mohammed, Diabetes in Oman: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification. Annals of Saudi Medicine. ,vol. 20, pp. 12- 15 ,(2000) , 10.5144/0256-4947.2000.12
B. E. Dunning, J. E. Foley, B. Ahrén, Alpha cell function in health and disease: influence of glucagon-like peptide-1 Diabetologia. ,vol. 48, pp. 1700- 1713 ,(2005) , 10.1007/S00125-005-1878-0
B. Ahren, R. Gomis, E. Standl, D. Mills, A. Schweizer, Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care. ,vol. 27, pp. 2874- 2880 ,(2004) , 10.2337/DIACARE.27.12.2874
Bo Ahrén, Mona Landin-Olsson, Per-Anders Jansson, Maria Svensson, David Holmes, Anja Schweizer, Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes The Journal of Clinical Endocrinology and Metabolism. ,vol. 89, pp. 2078- 2084 ,(2004) , 10.1210/JC.2003-031907
A. Mari, W. M. Sallas, Y. L. He, C. Watson, M. Ligueros-Saylan, B. E. Dunning, C. F. Deacon, J. J. Holst, J. E. Foley, Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes The Journal of Clinical Endocrinology and Metabolism. ,vol. 90, pp. 4888- 4894 ,(2005) , 10.1210/JC.2004-2460
S. Ristic, S. Byiers, J. Foley, D. Holmes, Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response Diabetes, Obesity and Metabolism. ,vol. 7, pp. 692- 698 ,(2005) , 10.1111/J.1463-1326.2005.00539.X
G. S. Meneilly, T. Elliott, D. Tessier, L. Hards, H. Tildesley, NIDDM in the Elderly Diabetes Care. ,vol. 19, pp. 1320- 1325 ,(1996) , 10.2337/DIACARE.19.12.1320
B. Ahren, G. Pacini, J. E. Foley, A. Schweizer, Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. ,vol. 28, pp. 1936- 1940 ,(2005) , 10.2337/DIACARE.28.8.1936
K. B. Degn, B. Brock, C. B. Juhl, C. B. Djurhuus, J. Grubert, D. Kim, J. Han, K. Taylor, M. Fineman, O. Schmitz, Effect of Intravenous Infusion of Exenatide (Synthetic Exendin-4) on Glucose-Dependent Insulin Secretion and Counterregulation During Hypoglycemia Diabetes. ,vol. 53, pp. 2397- 2403 ,(2004) , 10.2337/DIABETES.53.9.2397
M. G. Wulffele, A. Kooy, P. Lehert, D. Bets, J. C. Ogterop, B. Borger van der Burg, A. J.M. Donker, C. D.A. Stehouwer, Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes Diabetes Care. ,vol. 25, pp. 2133- 2140 ,(2002) , 10.2337/DIACARE.25.12.2133